Abeona Therapeutics (STU:PCJ) Payments of Debt: €-1.92 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PCJ Abeona Therapeutics Inc STU:PCJ
51 GF Score
Price €6.23
GF Value €15.12
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Abeona Therapeutics Payments of Debt?

Abeona Therapeutics STU:PCJ +4.32% 51 Payments of Debt is €-1.92 Mil as of Mar. 2026. GuruFocus rates STU:PCJ with a GF Score™ of 51/100 and a GF Value™ of €15.12 (Possible Value Trap). The stock has 8 warning signs investors should review.

Abeona Therapeutics's Payments of Debt for the three months ended in Mar. 2026 was €-1.92 Mil.

Abeona Therapeutics's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.92 Mil.

Abeona Therapeutics Payments of Debt Related Terms

Abeona Therapeutics Payments of Debt Historical Data

* Premium members only.

The historical data trend for Abeona Therapeutics's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abeona Therapeutics Payments of Debt Chart

Abeona Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Abeona Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.92
STU:PCJ
51GF Score
Abeona Therapeutics Inc STU:PCJ
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abeona Therapeutics Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €-1.92 Mil mean?
Abeona Therapeutics (STU:PCJ) has a Payments of Debt of €-1.92 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Abeona Therapeutics and its competitors.
Is Abeona Therapeutics' Payments of Debt too high?
Abeona Therapeutics' current Payments of Debt is €-1.92 Mil. Overall, Abeona Therapeutics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' Payments of Debt compare to RCKT and UPB?
Abeona Therapeutics' Payments of Debt of €-1.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Abeona Therapeutics and its competitors. Abeona Therapeutics's current Payments of Debt is €-1.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Abeona Therapeutics (STU:PCJ) is currently considered Possible Value Trap. The stock's GF Value™ is €15.12, compared to a current price of €6.23 — trading 58.8% below its estimated fair value. The current Payments of Debt is €-1.92 Mil. Abeona Therapeutics' overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Abeona Therapeutics (STU:PCJ), the current Payments of Debt is €-1.92 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abeona Therapeutics (STU:PCJ) Overvalued in 2026?

Based on GuruFocus' analysis, Abeona Therapeutics stock appears to be undervalued. The current stock price of €6.23 is trading 58.8% below its estimated GF Value™ of €15.12. GuruFocus considers Abeona Therapeutics to be Possible Value Trap.

Key valuation signals for STU:PCJ:

  • Payments of Debt: €-1.92 Mil
  • GF Value™: €15.12 vs. price of €6.23 (58.8% below fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the STU:PCJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abeona Therapeutics Business Description

Other Exchanges ABEO:USA0H7R:UK
Address 6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
51GF Score

Get the complete analysis for STU:PCJ

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.23
Price
€15.12
GF Value